Form 4: Forte Biosciences CFO Acquires Stock Options

Forte Biosciences CFO Antony A. Riley acquired 22,000 stock options with an exercise price of $17.15, vesting over four years starting June 16, 2026.

Summary

• Antony A. Riley, Chief Financial Officer of Forte Biosciences, Inc., acquired 22,000 stock options on June 16, 2026.
• The stock options have an exercise price of $17.15 per share.
• These options are subject to vesting over a four-year period, with full vesting on the fourth anniversary of the Vesting Commencement Date, which is June 16, 2026.
• The reporting person must remain a Service Provider to vest in the options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard executive compensation practice rather than a significant financial event.

Positives

• The CFO's acquisition of stock options indicates a belief in the company's future performance and potential stock appreciation.
• The vesting schedule over four years aligns the CFO's incentives with long-term company growth.

Risks

• The vesting of options is contingent on the reporting person continuing to be a Service Provider, meaning termination of employment could impact vesting.
• The exercise price of $17.15 implies that the stock price needs to exceed this level for the options to be profitable.

Future Outlook

The acquisition of stock options by the CFO suggests a positive outlook on the company's future prospects, as the value of these options is directly tied to the company's stock performance.

Industry Context

StockSavvy.ai notes that the granting of stock options to key executives like the CFO is a common practice in the biotechnology and pharmaceutical sectors to attract and retain talent, and to align executive interests with shareholder value.

Stakeholder Impact

• Shareholders: The acquisition of options by the CFO can be seen as a positive signal of management's confidence in the company's future, potentially aligning executive and shareholder interests.
• Employees: This filing is part of standard executive compensation and does not directly impact other employees.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• The reporting person will continue to vest in the stock options monthly, provided they remain a Service Provider.
• The options will be fully vested on June 16, 2030, assuming continued service.

Key Dates

Keywords

Forte Biosciences, FBRX, Form 4, Stock Options, Insider Trading, Executive Compensation, SEC Filing, Antony A. Riley, Chief Financial Officer